Tony Hagen is senior managing editor for The Center for Biosimilars®.
In a deal with Voluntis, Biocon Biologics aims to extend the appeal of its insulin products by offering a digital titration device for self-management of insulin dosage.
Biocon Biologics, specializing in biosimilars and insulin, said it has teamed up with Voluntis, a digital products health care company, to market an FDA-approved product that provides automated insulin dose recommendations to help individuals with diabetes self-manage their condition.
The product, Insulia, also enables health care teams to monitor by remote. It will be marketed to patients with type 2 diabetes using Biocon Biologics—brand insulins, which include recombinant human insulin, insulin glargine, and insulin aspart.
Under terms of the agreement, Biocon will distribute the product in several markets worldwide.
The company said Insulia is the first digital therapeutic with regulatory approval for providing automated titration recommendations for basal insulins. Insulia also has CE (Conformité Européenne) marking, meaning that it conforms to European Economic Area manufacturing standards.
“The demand for at-home treatment and telemedicine solutions is dramatically increasing around the world,” Biocon said in a statement.
“We believe pairing our products with a digital therapeutic solution will help improve patient outcomes and reduce costs to health care systems in the long term. We remain committed to impact patients’ lives through innovative solutions,” said Christiane Hamacher, CEO and managing director of Biocon.
Earlier this year, Biocon's parent company, Biocon Limited, announced plans to take the biosimilars unit public in an initial public offering of yet-undetermined valuation.